Search research articles
Contact Us
Filters
Showing results (61-70 of 80) with videos related to
Page
of 8
Sort By:
The Journal of Investigative Dermatology
|
April 14, 2022
Transcriptomic Analysis of the Major Orphan Ichthyosis Subtypes Reveals Shared Immune and Barrier Signatures
Madeline Kim, Daniela Mikhaylov, Stephanie M Rangel, et al.
Journal of the American Academy of Dermatology
|
February 11, 2023
Proteomic characterization of atopic dermatitis blood from infancy to adulthood
Ester Del Duca, Yael Renert-Yuval, Ana B Pavel, et al.
The British Journal of Dermatology
|
March 28, 2020
Frontal fibrosing alopecia shows robust T helper 1 and Janus kinase 3 skewing
E Del Duca, J Ruano Ruiz, A B Pavel, et al.
The Journal of Allergy and Clinical Immunology
|
December 5, 2021
Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers
Emma Guttman-Yassky, Ana B Pavel, Aisleen Diaz, et al.
Allergy
|
April 10, 2023
Age of onset defines two distinct profiles of atopic dermatitis in adults
Paola Facheris, Joel Correa Da Rosa, Angel D Pagan, et al.
The British Journal of Dermatology
|
March 29, 2019
The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study
R Bissonnette, C Maari, S Forman, et al.
The Journal of Allergy and Clinical Immunology
|
July 30, 2019
Oral Janus kinase/SYK inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitis
Ana B Pavel, Teresa Song, Hyun-Je Kim, et al.
The Journal of Allergy and Clinical Immunology
|
May 20, 2020
Phase 2 randomized, double-blind study of IL-17 targeting with secukinumab in atopic dermatitis
Benjamin Ungar, Ana B Pavel, Randall Li, et al.
Allergy
|
October 22, 2022
Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata
Yael Renert-Yuval, Ana B Pavel, Ester Del Duca, et al.
The Journal of Allergy and Clinical Immunology
|
April 14, 2018
Serum from Asian patients with atopic dermatitis is characterized by T<sub>H</sub>2/T<sub>H</sub>22 activation, which is highly correlated with nonlesional skin measures
Huei-Chi Wen, Tali Czarnowicki, Shinji Noda, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 80) with videos related to
Sort By:
Page
of 8
The Journal of Investigative Dermatology
|
April 14, 2022
Transcriptomic Analysis of the Major Orphan Ichthyosis Subtypes Reveals Shared Immune and Barrier Signatures
Madeline Kim, Daniela Mikhaylov, Stephanie M Rangel, et al.
Journal of the American Academy of Dermatology
|
February 11, 2023
Proteomic characterization of atopic dermatitis blood from infancy to adulthood
Ester Del Duca, Yael Renert-Yuval, Ana B Pavel, et al.
The British Journal of Dermatology
|
March 28, 2020
Frontal fibrosing alopecia shows robust T helper 1 and Janus kinase 3 skewing
E Del Duca, J Ruano Ruiz, A B Pavel, et al.
The Journal of Allergy and Clinical Immunology
|
December 5, 2021
Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers
Emma Guttman-Yassky, Ana B Pavel, Aisleen Diaz, et al.
Allergy
|
April 10, 2023
Age of onset defines two distinct profiles of atopic dermatitis in adults
Paola Facheris, Joel Correa Da Rosa, Angel D Pagan, et al.
The British Journal of Dermatology
|
March 29, 2019
The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study
R Bissonnette, C Maari, S Forman, et al.
The Journal of Allergy and Clinical Immunology
|
July 30, 2019
Oral Janus kinase/SYK inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitis
Ana B Pavel, Teresa Song, Hyun-Je Kim, et al.
The Journal of Allergy and Clinical Immunology
|
May 20, 2020
Phase 2 randomized, double-blind study of IL-17 targeting with secukinumab in atopic dermatitis
Benjamin Ungar, Ana B Pavel, Randall Li, et al.
Allergy
|
October 22, 2022
Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata
Yael Renert-Yuval, Ana B Pavel, Ester Del Duca, et al.
The Journal of Allergy and Clinical Immunology
|
April 14, 2018
Serum from Asian patients with atopic dermatitis is characterized by T<sub>H</sub>2/T<sub>H</sub>22 activation, which is highly correlated with nonlesional skin measures
Huei-Chi Wen, Tali Czarnowicki, Shinji Noda, et al.
Page
of 8